Anne Rowzee

Associate Director for Policy, Office of Tissues and Advanced Therapies • FDA

Anne M. Rowzee, Ph.D. joined the Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies in October 2018 as an Associate Director for Policy. Dr. Rowzee directs OTAT’s stakeholder proactive outreach and engagement program. As part of OTAT’s patient-focused outreach, Dr. Rowzee has launched the regenerative medicine therapy outreach and education campaign, including the #RegenMedEd patient webinar series and annual patient workshops. Recently, Dr. Rowzee launched OTAT’s Virtual Town Hall Series to engage with product development stakeholders and provide regulatory information to advance drug development. Before moving to CBER, Anne was a Science Policy analyst in the Office of Therapeutic Biologics and Biosimilars in the Center for Drug Evaluation and Research where she provided scientific guidance to ensure consistency in agency recommendations across biosimilar development programs. Dr. Rowzee joined FDA in 2011, spearheading communications covering CDER regulatory and research programs for the Office of Communications. During her time in OCOMM, Dr. Rowzee wrote and directed manuscripts for high-visibility peer-reviewed journals and led the OCOMM Editorial Team.

Also Speaking

Pierre Boulas

Head of Medical Devices and Packaging Development • Biogen

Justin Skoble

Vice President, Head of Technical Operations • Caribou Biosciences

Matthew Li

Director, Cell Therapy CMC • Tome Biosciences

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.